311 related articles for article (PubMed ID: 3121519)
1. Bacteriological effects of anti-Pseudomonas aeruginosa chemotherapy in cystic fibrosis.
Bauernfeind A; Emminger G; Hörl G; Ott S; Przyklenk B; Weisslein-Pfister C
Infection; 1987; 15(5):403-6. PubMed ID: 3121519
[TBL] [Abstract][Full Text] [Related]
2. Routine susceptibility testing of four antibiotic combinations for improvement of laboratory guide to therapy of cystic fibrosis infections caused by Pseudomonas aeruginosa.
Weiss K; Lapointe JR
Antimicrob Agents Chemother; 1995 Nov; 39(11):2411-4. PubMed ID: 8585718
[TBL] [Abstract][Full Text] [Related]
3. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.
Waters V; Ratjen F
Cochrane Database Syst Rev; 2012 Nov; 11():CD009528. PubMed ID: 23152277
[TBL] [Abstract][Full Text] [Related]
4. Penicillin-binding protein 3 is a common adaptive target among Pseudomonas aeruginosa isolates from adult cystic fibrosis patients treated with β-lactams.
Clark ST; Sinha U; Zhang Y; Wang PW; Donaldson SL; Coburn B; Waters VJ; Yau YCW; Tullis DE; Guttman DS; Hwang DM
Int J Antimicrob Agents; 2019 May; 53(5):620-628. PubMed ID: 30664925
[TBL] [Abstract][Full Text] [Related]
5. Does ivacaftor interfere with the antimicrobial activity of commonly used antibiotics against Pseudomonas aeruginosa?-Results of an in vitro study.
Millar BC; Rendall JC; Downey DG; Moore JE
J Clin Pharm Ther; 2018 Dec; 43(6):836-843. PubMed ID: 29959786
[TBL] [Abstract][Full Text] [Related]
6. Mixed morphotype susceptibility testing of Pseudomonas aeruginosa from patients with cystic fibrosis.
Dunne WM; Chusid MJ
Diagn Microbiol Infect Dis; 1987 Feb; 6(2):165-70. PubMed ID: 3102157
[TBL] [Abstract][Full Text] [Related]
7. Are antipseudomonal antibiotics really beneficial in acute respiratory exacerbations of cystic fibrosis?
Wolter JM; Bowler SD; McCormack JG
Aust N Z J Med; 1999 Feb; 29(1):15-21. PubMed ID: 10200808
[TBL] [Abstract][Full Text] [Related]
8. Pseudomonas aeruginosa antibiotic resistance in Australian cystic fibrosis centres.
Smith DJ; Ramsay KA; Yerkovich ST; Reid DW; Wainwright CE; Grimwood K; Bell SC; Kidd TJ
Respirology; 2016 Feb; 21(2):329-37. PubMed ID: 26711802
[TBL] [Abstract][Full Text] [Related]
9. Ceftolozane/tazobactam sensitivity patterns in Pseudomonas aeruginosa isolates recovered from sputum of cystic fibrosis patients.
Finklea JD; Hollaway R; Lowe K; Lee F; Le J; Jain R
Diagn Microbiol Infect Dis; 2018 Sep; 92(1):75-77. PubMed ID: 29884565
[TBL] [Abstract][Full Text] [Related]
10. [Antibiotic therapy of cystic fibrosis in children].
Kapranov NI; Shabalova LA; Kashirskaia NIu; SimonovaO OI; Voronkova AIu; Osipova IA; Semykin SIu; Polikarpova SV; Postnikov SS
Antibiot Khimioter; 2001; 46(2):26-32. PubMed ID: 11544748
[TBL] [Abstract][Full Text] [Related]
11. Expression of Pseudomonas aeruginosa Antibiotic Resistance Genes Varies Greatly during Infections in Cystic Fibrosis Patients.
Martin LW; Robson CL; Watts AM; Gray AR; Wainwright CE; Bell SC; Ramsay KA; Kidd TJ; Reid DW; Brockway B; Lamont IL
Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30201819
[TBL] [Abstract][Full Text] [Related]
12. Adaptive resistance to tobramycin in Pseudomonas aeruginosa lung infection in cystic fibrosis.
Barclay ML; Begg EJ; Chambers ST; Thornley PE; Pattemore PK; Grimwood K
J Antimicrob Chemother; 1996 Jun; 37(6):1155-64. PubMed ID: 8836818
[TBL] [Abstract][Full Text] [Related]
13. An epidemic spread of multiresistant Pseudomonas aeruginosa in a cystic fibrosis centre.
Pedersen SS; Koch C; Høiby N; Rosendal K
J Antimicrob Chemother; 1986 Apr; 17(4):505-16. PubMed ID: 3086274
[TBL] [Abstract][Full Text] [Related]
14. Rational parameters for antibiotic therapy in patients with cystic fibrosis.
Govan JR; Doherty C; Glass S
Infection; 1987; 15(4):300-7. PubMed ID: 3117704
[TBL] [Abstract][Full Text] [Related]
15. Pseudomonas aeruginosa in cystic fibrosis patients with c.1652G›A (G551D)-CFTR treated with ivacaftor-Changes in microbiological parameters.
Millar BC; McCaughan J; Rendall JC; Downey DG; Moore JE
J Clin Pharm Ther; 2018 Feb; 43(1):92-100. PubMed ID: 29293275
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the E test for the assessment of synergy of antibiotic combinations against multiresistant Pseudomonas aeruginosa isolates from cystic fibrosis patients.
Balke B; Hogardt M; Schmoldt S; Hoy L; Weissbrodt H; Häussler S
Eur J Clin Microbiol Infect Dis; 2006 Jan; 25(1):25-30. PubMed ID: 16402226
[TBL] [Abstract][Full Text] [Related]
17. Correlation between activity of beta-lactam agents in vitro and bacteriological outcome in acute pulmonary exacerbations of cystic fibrosis.
Gaillard JL; Cahen P; Delacourt C; Silly C; Le Bourgeois M; Coustère C; de Blic J; Lenoir G; Scheinmann P
Eur J Clin Microbiol Infect Dis; 1995 Apr; 14(4):291-6. PubMed ID: 7649191
[TBL] [Abstract][Full Text] [Related]
18. Antimicrobials in cystic fibrosis: emergence of resistance and implications for treatment.
Zabner R; Quinn JP
Semin Respir Infect; 1992 Sep; 7(3):210-7. PubMed ID: 1475544
[TBL] [Abstract][Full Text] [Related]
19. Pseudomonas colonization in cystic fibrosis. A study of 160 patients.
Kulczycki LL; Murphy TM; Bellanti JA
JAMA; 1978 Jul; 240(1):30-4. PubMed ID: 96277
[TBL] [Abstract][Full Text] [Related]
20. Accuracy and cost of antibiotic susceptibility testing of mixed morphotypes of Pseudomonas aeruginosa.
Morlin GL; Hedges DL; Smith AL; Burns JL
J Clin Microbiol; 1994 Apr; 32(4):1027-30. PubMed ID: 8027305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
